Deutsche Bank Ag\ Xeris Biopharma Holdings, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 127,600 shares of XERS stock, worth $478,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares

127,600

Previous 79,532 60.44%

Holding current value

$478,500

Previous $226,000 91.15%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.78 - $3.73 $133,629 - $179,293	48,068 Added 60.44%	127,600 $432,000
Q3 2024 Nov 13, 2024	BUY	$2.06 - $2.96 $49,915 - $71,723	24,231 Added 43.82%	79,532 $226,000
Q2 2024 Aug 14, 2024	SELL	$1.7 - $2.45 $22,511 - $32,442	-13,242 Reduced 19.32%	55,301 $124,000
Q1 2024 May 15, 2024	BUY	$2.04 - $3.22 $5,026 - $7,934	2,464 Added 3.73%	68,543 $151,000
Q4 2023 Feb 14, 2024	SELL	$1.47 - $2.36 $2,942 - $4,724	-2,002 Reduced 2.94%	66,079 $155,000
Q3 2023 Nov 09, 2023	BUY	$1.8 - $2.69 $18,365 - $27,446	10,203 Added 17.63%	68,081 $126,000
Q2 2023 Aug 14, 2023	SELL	$1.82 - $2.98 $56,378 - $92,311	-30,977 Reduced 34.86%	57,878 $151,000
Q1 2023 May 15, 2023	BUY	$1.03 - $1.63 $31,137 - $49,276	30,231 Added 51.57%	88,855 $144,000
Q4 2022 Feb 13, 2023	BUY	$1.14 - $1.65 $1,006 - $1,456	883 Added 1.53%	58,624 $77,000
Q3 2022 Nov 14, 2022	SELL	$1.37 - $1.93 $12,109 - $17,059	-8,839 Reduced 13.28%	57,741 $90,000
Q2 2022 Aug 11, 2022	BUY	$1.48 - $2.64 $98,538 - $175,771	66,580 New	66,580 $102,000

Others Institutions Holding XERS

# of Institutions

163

Shares Held

61.5M

Call Options Held

34.2K

Put Options Held

21.7K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $510M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account